Universal Display Corporation ( OLED Quick Quote OLED - Free Report) is scheduled to report fourth-quarter 2019 results on Feb 20. The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 72 cents per share, unchanged over the last 30 days. The figure indicates an improvement of 80% from the year-ago reported figure. The Zacks Consensus Estimate for revenues stands at $97.36 million, suggesting growth of 38.8% from the year-ago quarter. Notably, the company beat estimates in the trailing four quarters by 77.09%, on average. Coming to the price performance, shares of Universal Display have returned 50.3% in the past year, significantly outperforming the industry's growth of 15.6%. Factors Likely to Have Influenced Q4 Results Universal Display’s fourth-quarter top-line performance is expected to have gained from ongoing momentum in material sales, green emitter and red emitter sales. Moreover, contribution from the company’s OLED host partnerships is likely to have driven Material sales. In the last reported quarter, Material sales improved 1.2% year over year to $51.8 million. Markedly, the Zacks Consensus Estimate for Material sales for the third quarter is currently pegged at $59 million, suggesting growth of 47.9% from the year-ago reported figure. The company’s fourth-quarter top-line is likely to have benefited from robust demand across end-markets, comprising smartphones, television, virtual reality (VR) devices and automotive markets. In this regard, growing proliferation of advanced driver assisted systems (ADAS) in autonomous cars, rapid adoption of cloud, IoT, and accelerated deployment of 5G is expected to have been a tailwind. Additionally, new OLED-based product launches from premium device makers like Apple, Huawei, OPPO, Samsung, and VIVO, and increasing capacity of OLED in TV are anticipated to have aided order growth rate. This, in turn, is likely to get reflected in the fourth-quarter performance. Moreover, synergies from Adesis acquisition is expected to get reflected in the fourth-quarter results. Notably, Adesis had contributed $2.7 million to the third-quarter top line (2.8% of third-quarter revenues). Markedly, the Zacks Consensus Estimate for Contract Research Services revenues for the fourth quarter is currently pegged at $4.7 million, suggesting an improvement of 7.3% from the year-ago reported figure.
However, longer lead times are likely to have limited licensing revenues growth.
Notably, the Zacks Consensus Estimate for revenues from Royalty and License Fees for the fourth quarter is currently pegged at $35.3 million, indicating growth of 36.3% from the year-ago reported figure. What Our Model Says Our proven model does not conclusively predict an earnings beat for Universal Display this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. Universal Display has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Stocks to Consider Here are a few stocks that you may consider, as our proven model shows that these have the right combination of elements to post an earnings beat this quarter. Builders FirstSource, Inc. ( BLDR Quick Quote BLDR - Free Report) has an Earnings ESP of +1.45% and a Zacks Rank of 1. You can see . the complete list of today’s Zacks #1 Rank stocks here Casa Systems, Inc. ( CASA Quick Quote CASA - Free Report) has an Earnings ESP of +8.34% and a Zacks Rank of 2. Alarm.com Holdings, Inc. ( ALRM Quick Quote ALRM - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #2. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>